Molecular Markers of Early Parkinson's Disease Based on Gene Expression in Blood

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2007 Jan 12

PMID 17215369

Citations 213

Authors

Clemens R Scherzer

Aron C Eklund

Lee J Morse

Zhixiang Liao

Joseph J Locascio

Daniel Fefer

Michael A Schwarzschild

Michael G Schlossmacher

Michael A Hauser

Jeffery M Vance

Lewis R Sudarsky

David G Standaert

John H Growdon

Roderick V Jensen

Steven R Gullans

Affiliations

Soon will be listed here.

Abstract

Parkinson's disease (PD) progresses relentlessly and affects five million people worldwide. Laboratory tests for PD are critically needed for developing treatments designed to slow or prevent progression of the disease. We performed a transcriptome-wide scan in 105 individuals to interrogate the molecular processes perturbed in cellular blood of patients with early-stage PD. The molecular multigene marker here identified is associated with risk of PD in 66 samples of the training set comprising healthy and disease controls [third tertile cross-validated odds ratio of 5.7 (P for trend 0.005)]. It is further validated in 39 independent test samples [third tertile odds ratio of 5.1 (P for trend 0.04)]. Insights into disease-linked processes detectable in peripheral blood are offered by 22 unique genes differentially expressed in patients with PD versus healthy individuals. These include the co-chaperone ST13, which stabilizes heat-shock protein 70, a modifier of alpha-synuclein misfolding and toxicity. ST13 messenger RNA copies are lower in patients with PD (mean +/- SE 0.59 +/- 0.05) than in controls (0.96 +/- 0.09) (P = 0.002) in two independent populations. Thus, gene expression signals measured in blood can facilitate the development of biomarkers for PD.

Citing Articles

Uncovering Potential Biomarkers and Constructing a Prediction Model Associated with Iron Metabolism in Parkinson's Disease.

Cheng Y, Zhai H, Liu Y, Yang Y, Fang B, Song M Neuropsychiatr Dis Treat. 2025; 21:437-449.

PMID: 40041883 PMC: 11878125. DOI: 10.2147/NDT.S511671.

Glycolytic pathways: The hidden regulators in Parkinson's disease.

Shen J, Yao E, Tian W, He J, Gu Y, Zhao D Heliyon. 2025; 11(3):e41831.

PMID: 39959499 PMC: 11830313. DOI: 10.1016/j.heliyon.2025.e41831.

Motor Functional Hierarchical Organization of Cerebrum and Its Underlying Genetic Architecture in Parkinson's Disease.

Bu S, Li X, Pang H, Zhao M, Wang J, Liu Y J Neurosci. 2025; 45(7).

PMID: 39824632 PMC: 11823334. DOI: 10.1523/JNEUROSCI.1492-24.2024.

Transcriptomic analysis of melanoma cells reveals an association of α-synuclein with regulation of the inflammatory response.

Rajasekaran S, Cheng S, Gajendran N, Shekoohi S, Chesnokova L, Yu X Sci Rep. 2024; 14(1):27140.

PMID: 39511366 PMC: 11544018. DOI: 10.1038/s41598-024-78777-6.

Exploring circular RNAs as biomarkers for Parkinson's disease and their expression changes after aerobic exercise rehabilitation.

de Abreu F, de Oliveira D, de Araujo Romero Ferrari S, E Silva K, Titze-de-Almeida R, Titze-de-Almeida S Funct Integr Genomics. 2024; 24(4):130.

PMID: 39069524 DOI: 10.1007/s10142-024-01409-9.

References

Scherzer C, Offe K, Gearing M, Rees H, Fang G, Heilman C . Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol. 2004; 61(8):1200-5. DOI: 10.1001/archneur.61.8.1200. View

Ransohoff D . Rules of evidence for cancer molecular-marker discovery and validation. Nat Rev Cancer. 2004; 4(4):309-14. DOI: 10.1038/nrc1322. View

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

Schulz J, Beal M . Mitochondrial dysfunction in movement disorders. Curr Opin Neurol. 1994; 7(4):333-9. DOI: 10.1097/00019052-199408000-00010. View

Hohfeld J, Minami Y, Hartl F . Hip, a novel cochaperone involved in the eukaryotic Hsc70/Hsp40 reaction cycle. Cell. 1995; 83(4):589-98. DOI: 10.1016/0092-8674(95)90099-3. View

Nagai Y, Ueno S, Saeki Y, Soga F, Hirano M, Yanagihara T . Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology. 1996; 46(3):791-5. DOI: 10.1212/wnl.46.3.791. View

Kalchman M, Graham R, Xia G, Koide H, Hodgson J, Graham K . Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem. 1996; 271(32):19385-94. DOI: 10.1074/jbc.271.32.19385. View

Rocca W, Maraganore D, McDonnell S, Schaid D . Validation of a telephone questionnaire for Parkinson's disease. J Clin Epidemiol. 1998; 51(6):517-23. DOI: 10.1016/s0895-4356(98)00017-1. View

Sunada Y, Saito F, Matsumura K, Shimizu T . Differential expression of the parkin gene in the human brain and peripheral leukocytes. Neurosci Lett. 1999; 254(3):180-2. DOI: 10.1016/s0304-3940(98)00697-1. View

10.

Barbanti P, Fabbrini G, Ricci A, Cerbo R, Bronzetti E, Caronti B . Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord. 1999; 14(5):764-71. DOI: 10.1002/1531-8257(199909)14:5<764::aid-mds1008>3.0.co;2-w. View

11.

Sorkina T, Hoover B, Zahniser N, Sorkin A . Constitutive and protein kinase C-induced internalization of the dopamine transporter is mediated by a clathrin-dependent mechanism. Traffic. 2005; 6(2):157-70. DOI: 10.1111/j.1600-0854.2005.00259.x. View

12.

Michiels S, Koscielny S, Hill C . Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005; 365(9458):488-92. DOI: 10.1016/S0140-6736(05)17866-0. View

13.

Kim J, Kim Y, Song C, Yoon I, Park J, Choi Y . Association of vitamin D receptor gene polymorphism and Parkinson's disease in Koreans. J Korean Med Sci. 2005; 20(3):495-8. PMC: 2782210. DOI: 10.3346/jkms.2005.20.3.495. View

14.

Hauser M, Li Y, Xu H, Noureddine M, Shao Y, Gullans S . Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism. Arch Neurol. 2005; 62(6):917-21. DOI: 10.1001/archneur.62.6.917. View

15.

Shin Y, Klucken J, Patterson C, Hyman B, McLean P . The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem. 2005; 280(25):23727-34. DOI: 10.1074/jbc.M503326200. View

16.

Schadt E, Lamb J, Yang X, Zhu J, Edwards S, GuhaThakurta D . An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005; 37(7):710-7. PMC: 2841396. DOI: 10.1038/ng1589. View

17.

Flower T, Chesnokova L, Froelich C, Dixon C, Witt S . Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol. 2005; 351(5):1081-100. DOI: 10.1016/j.jmb.2005.06.060. View

18.

Forman M, Lee V, Trojanowski J . Nosology of Parkinson's disease: looking for the way out of a quagmire. Neuron. 2005; 47(4):479-82. DOI: 10.1016/j.neuron.2005.07.021. View

19.

Andersen O, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J . Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A. 2005; 102(38):13461-6. PMC: 1224625. DOI: 10.1073/pnas.0503689102. View

20.

Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G . Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci. 2005; 1053:356-75. DOI: 10.1196/annals.1344.031. View